Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jun. 30, 2022 | Aug. 01, 2022 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2022 | |
Document Transition Report | false | |
Entity File Number | 001-39801 | |
Entity Registrant Name | XOMA Corporation | |
Entity Incorporation State Country Code | DE | |
Entity Tax Identification Number | 52-2154066 | |
Entity Address Address Line1 | 2200 Powell Street | |
Entity Address Address Line2 | Suite 310 | |
Entity Address City Or Town | Emeryville | |
Entity Address State Or Province | CA | |
Entity Address Postal Zip Code | 94608 | |
City Area Code | 510 | |
Local Phone Number | 204-7200 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 11,450,823 | |
Entity Central Index Key | 0000791908 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q2 | |
Amendment Flag | false | |
Common Stock | ||
Security12b Title | Common Stock, $0.0075 par value | |
Trading Symbol | XOMA | |
Security Exchange Name | NASDAQ | |
8.625% Series A Cumulative, Perpetual Preferred Stock | ||
Security12b Title | 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 | |
Trading Symbol | XOMAP | |
Security Exchange Name | NASDAQ | |
Series B Depositary Shares | ||
Security12b Title | Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05) | |
Trading Symbol | XOMAO | |
Security Exchange Name | NASDAQ |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 83,182 | $ 93,328 |
Restricted cash | 2,049 | |
Short-term equity securities | 523 | 774 |
Trade and other receivables, net | 5 | 209 |
Short-term royalty and commercial payment receivables | 2,500 | 0 |
Prepaid expenses and other current assets | 1,051 | 613 |
Total current assets | 87,261 | 96,973 |
Property and equipment, net | 10 | 13 |
Operating lease right-of-use assets | 116 | 200 |
Long-term royalty and commercial payment receivables | 66,575 | 69,075 |
Other assets - long term | 260 | 301 |
Total assets | 154,222 | 166,562 |
Current liabilities: | ||
Accounts payable | 1,153 | 1,072 |
Accrued and other liabilities | 1,026 | 525 |
Income taxes payable | 91 | |
Contingent consideration under RPAs and CPPAs | 3,075 | 8,075 |
Operating lease liabilities | 133 | 195 |
Unearned revenue recognized under units-of-revenue method | 1,669 | 1,641 |
Preferred stock dividend accrual | 1,368 | 1,368 |
Total current liabilities | 8,424 | 12,967 |
Unearned revenue recognized under units-of-revenue method - long-term | 10,842 | 11,685 |
Long-term operating lease liabilities | 34 | |
Total liabilities | 19,266 | 24,686 |
Commitments and Contingencies (Note 9) | ||
Stockholders' equity: | ||
Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,423,823 and 11,315,263 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively | 86 | 85 |
Additional paid-in capital | 1,307,059 | 1,307,030 |
Accumulated deficit | (1,172,238) | (1,165,288) |
Total stockholders' equity | 134,956 | 141,876 |
Total liabilities and stockholders' equity | 154,222 | 166,562 |
8.625% Series A Cumulative, Perpetual Preferred Stock | ||
Stockholders' equity: | ||
Preferred Stock | 49 | 49 |
8.375% Series B Cumulative, Perpetual Preferred Stock | ||
Stockholders' equity: | ||
Preferred Stock | ||
Convertible preferred stock | ||
Stockholders' equity: | ||
Preferred Stock |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Preferred stock, par value (in dollars per share) | $ 0.05 | $ 0.05 |
Preferred stock, shares authorized (in shares) | 1,000,000 | 1,000,000 |
Common stock, par value (in dollars per share) | $ 0.0075 | $ 0.0075 |
Common stock, shares authorized (in shares) | 277,333,332 | 277,333,332 |
Common stock, shares issued (in shares) | 11,423,823 | 11,315,263 |
Common stock, shares outstanding (in shares) | 11,423,823 | 11,315,263 |
8.625% Series A Cumulative, Perpetual Preferred Stock | ||
Preferred stock, dividend rate (as a percent) | 8.625% | 8.625% |
Preferred stock, shares issued (in shares) | 984,000 | 984,000 |
Preferred stock, shares outstanding (in shares) | 984,000 | 984,000 |
8.375% Series B Cumulative, Perpetual Preferred Stock | ||
Preferred stock, dividend rate (as a percent) | 8.375% | 8.375% |
Preferred stock, shares issued (in shares) | 1,600 | 1,600 |
Preferred stock, shares outstanding (in shares) | 1,600 | 1,600 |
Convertible preferred stock | ||
Preferred stock, shares issued (in shares) | 5,003 | 5,003 |
Preferred stock, shares outstanding (in shares) | 5,003 | 5,003 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Revenues: | ||||
Revenue from contracts with customers | $ 525 | $ 525 | $ 3,275 | $ 544 |
Revenue recognized under units-of-revenue method | 458 | 376 | 815 | 731 |
Total revenues | 983 | 901 | 4,090 | 1,275 |
Operating expenses: | ||||
Research and development | 40 | 38 | 96 | 99 |
General and administrative | 5,710 | 3,927 | 10,826 | 10,667 |
Total operating expenses | 5,750 | 3,965 | 10,922 | 10,766 |
Loss from operations | (4,767) | (3,064) | (6,832) | (9,491) |
Other income (expense), net: | ||||
Interest expense | (172) | (461) | ||
Loss on extinguishment of debt | (300) | (300) | ||
Other income (expense), net | 97 | 1,299 | (118) | 642 |
Net loss | (4,670) | (2,237) | (6,950) | (9,610) |
Net comprehensive loss | (4,670) | (2,237) | (6,950) | (9,610) |
Less: accumulated dividends on Series A and Series B preferred stock | (1,368) | (1,293) | (2,736) | (1,824) |
Net loss attributable to common stockholders, basic | (6,038) | (3,530) | (9,686) | (11,434) |
Net loss attributable to common stockholders, diluted | $ (6,038) | $ (3,530) | $ (9,686) | $ (11,434) |
Basic net loss per share attributable to common stockholders (in dollars per share) | $ (0.53) | $ (0.31) | $ (0.85) | $ (1.02) |
Diluted net loss per share attributable to common stockholders (in dollars per share) | $ (0.53) | $ (0.31) | $ (0.85) | $ (1.02) |
Weighted average shares used in computing basic net loss per share attributable to common stockholders | 11,421 | 11,285 | 11,376 | 11,263 |
Weighted average shares used in computing diluted net loss per share attributable to common stockholders | 11,421 | 11,285 | 11,376 | 11,263 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands | Preferred Stock 8.625% Series A Cumulative, Perpetual Preferred Stock | Preferred Stock 8.375% Series B Cumulative, Perpetual Preferred Stock | Preferred Stock Convertible preferred stock | Common Stock | Additional Paid-In Capital | Accumulated Deficit | Total |
Balance at beginning of period at Dec. 31, 2020 | $ 49 | $ 84 | $ 1,267,377 | $ (1,181,086) | $ 86,424 | ||
Balance at beginning of period (in shares) at Dec. 31, 2020 | 984,000 | 5,000 | 11,229,000 | ||||
Increase (Decrease) in Stockholders' Equity | |||||||
Exercise of stock options | 388 | 388 | |||||
Exercise of stock options (in shares) | 24,000 | ||||||
Exercise of common stock warrants (in shares) | 5,000 | ||||||
Issuance of common stock related to 401(k) contribution | 90 | 90 | |||||
Issuance of common stock related to 401(k) contribution (in shares) | 2,000 | ||||||
Stock-based compensation expense | 2,898 | 2,898 | |||||
Preferred stock dividends | (707) | (707) | |||||
Net loss and comprehensive loss | (7,373) | (7,373) | |||||
Balance at end of period at Mar. 31, 2021 | $ 49 | $ 84 | 1,270,046 | (1,188,459) | 81,720 | ||
Balance at end of period (in shares) at Mar. 31, 2021 | 984,000 | 5,000 | 11,260,000 | ||||
Balance at beginning of period at Dec. 31, 2020 | $ 49 | $ 84 | 1,267,377 | (1,181,086) | 86,424 | ||
Balance at beginning of period (in shares) at Dec. 31, 2020 | 984,000 | 5,000 | 11,229,000 | ||||
Increase (Decrease) in Stockholders' Equity | |||||||
Net loss and comprehensive loss | (9,610) | ||||||
Balance at end of period at Jun. 30, 2021 | $ 49 | $ 85 | 1,307,140 | (1,190,696) | 116,578 | ||
Balance at end of period (in shares) at Jun. 30, 2021 | 984,000 | 2,000 | 5,000 | 11,310,000 | |||
Balance at beginning of period at Mar. 31, 2021 | $ 49 | $ 84 | 1,270,046 | (1,188,459) | 81,720 | ||
Balance at beginning of period (in shares) at Mar. 31, 2021 | 984,000 | 5,000 | 11,260,000 | ||||
Increase (Decrease) in Stockholders' Equity | |||||||
Exercise of stock options | $ 1 | 593 | 594 | ||||
Exercise of stock options (in shares) | 49,000 | ||||||
Issuance of common stock related to ESPP | 17 | 17 | |||||
Issuance of common stock related to ESPP (in shares) | 1,000 | ||||||
Stock-based compensation expense | 768 | 768 | |||||
Issuance of stock | 37,140 | 37,140 | |||||
Issuance of stock, net (in shares) | 2,000 | ||||||
Preferred stock dividends | (1,424) | (1,424) | |||||
Net loss and comprehensive loss | (2,237) | (2,237) | |||||
Balance at end of period at Jun. 30, 2021 | $ 49 | $ 85 | 1,307,140 | (1,190,696) | 116,578 | ||
Balance at end of period (in shares) at Jun. 30, 2021 | 984,000 | 2,000 | 5,000 | 11,310,000 | |||
Balance at beginning of period at Dec. 31, 2021 | $ 49 | $ 85 | 1,307,030 | (1,165,288) | 141,876 | ||
Balance at beginning of period (in shares) at Dec. 31, 2021 | 984,000 | 2,000 | 5,000 | 11,315,000 | |||
Increase (Decrease) in Stockholders' Equity | |||||||
Exercise of stock options | $ 1 | 632 | 633 | ||||
Exercise of stock options (in shares) | 91,000 | ||||||
Issuance of common stock related to 401(k) contribution | 85 | 85 | |||||
Issuance of common stock related to 401(k) contribution (in shares) | 4,000 | ||||||
Stock-based compensation expense | 978 | 978 | |||||
Preferred stock dividends | (1,368) | (1,368) | |||||
Net loss and comprehensive loss | (2,280) | (2,280) | |||||
Balance at end of period at Mar. 31, 2022 | $ 49 | $ 86 | 1,307,357 | (1,167,568) | 139,924 | ||
Balance at end of period (in shares) at Mar. 31, 2022 | 984,000 | 2,000 | 5,000 | 11,410,000 | |||
Balance at beginning of period at Dec. 31, 2021 | $ 49 | $ 85 | 1,307,030 | (1,165,288) | $ 141,876 | ||
Balance at beginning of period (in shares) at Dec. 31, 2021 | 984,000 | 2,000 | 5,000 | 11,315,000 | |||
Increase (Decrease) in Stockholders' Equity | |||||||
Exercise of stock options (in shares) | 101,811 | ||||||
Net loss and comprehensive loss | $ (6,950) | ||||||
Balance at end of period at Jun. 30, 2022 | $ 49 | $ 86 | 1,307,059 | (1,172,238) | 134,956 | ||
Balance at end of period (in shares) at Jun. 30, 2022 | 984,000 | 2,000 | 5,000 | 11,424,000 | |||
Balance at beginning of period at Mar. 31, 2022 | $ 49 | $ 86 | 1,307,357 | (1,167,568) | 139,924 | ||
Balance at beginning of period (in shares) at Mar. 31, 2022 | 984,000 | 2,000 | 5,000 | 11,410,000 | |||
Increase (Decrease) in Stockholders' Equity | |||||||
Exercise of stock options | 189 | 189 | |||||
Exercise of stock options (in shares) | 11,000 | ||||||
Issuance of common stock related to ESPP | 45 | 45 | |||||
Issuance of common stock related to ESPP (in shares) | 3,000 | ||||||
Stock-based compensation expense | 836 | 836 | |||||
Preferred stock dividends | (1,368) | (1,368) | |||||
Net loss and comprehensive loss | (4,670) | (4,670) | |||||
Balance at end of period at Jun. 30, 2022 | $ 49 | $ 86 | $ 1,307,059 | $ (1,172,238) | $ 134,956 | ||
Balance at end of period (in shares) at Jun. 30, 2022 | 984,000 | 2,000 | 5,000 | 11,424,000 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Cash flows from operating activities: | ||
Net loss | $ (6,950) | $ (9,610) |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Stock-based compensation expense | 1,815 | 3,666 |
Common stock contribution to 401(k) | 85 | 90 |
Depreciation | 3 | 4 |
Amortization of debt issuance costs, debt discount and final payment on debt | 200 | |
Non-cash lease expense | 84 | 79 |
Loss on extinguishment of debt | 300 | |
Change in fair value of equity securities | 251 | (617) |
Changes in assets and liabilities: | ||
Trade and other receivables, net | 204 | 251 |
Income tax receivable | 1,526 | |
Prepaid expenses and other assets | (398) | (701) |
Accounts payable and accrued liabilities | 582 | 748 |
Income tax payable | (91) | |
Operating lease liabilities | (96) | (88) |
Unearned revenue recognized under units-of-revenue method | (815) | (731) |
Other liabilities | (6) | |
Net cash used in operating activities | (5,326) | (4,889) |
Cash flows from investing activities: | ||
Payment of contingent consideration under RPAs and CPPAs | (5,000) | |
Payments related to purchase of royalty rights and other commercial payment rights | (13,500) | |
Net cash used in investing activities | (5,000) | (13,500) |
Cash flows from financing activities: | ||
Proceeds from issuance of preferred stock | 40,000 | |
Payment of preferred stock dividends | (2,736) | (707) |
Payment of preferred and common stock issuance costs | (3,106) | |
Proceeds from exercise of options | 1,905 | 1,355 |
Taxes paid related to net share settlement of equity awards | (1,038) | (355) |
Principal payments - debt | (4,250) | |
Payment for extinguishment of debt | (17,103) | |
Payment for debt modification fee | (24) | |
Net cash (used in) provided by financing activities | (1,869) | 15,810 |
Net decrease in cash, cash equivalents and restricted cash | (12,195) | (2,579) |
Cash and restricted cash at the beginning of the period | 95,377 | 86,364 |
Cash, cash equivalents and restricted cash at the end of the period | 83,182 | 83,785 |
Supplemental Cash Flow Information: | ||
Cash paid for taxes | 95 | |
Cash paid for interest | 311 | |
Non-cash investing and financing activities: | ||
Preferred stock dividend accrual | $ 1,368 | 1,424 |
Accrued cost related to issuance of preferred stock | $ 105 |
Description of Business
Description of Business | 6 Months Ended |
Jun. 30, 2022 | |
Description of Business | |
Description of Business | 1. Description of Business XOMA, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. The Company’s portfolio was built through licensing its proprietary products and platforms from its legacy discovery and development business, combined with the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs. Liquidity and Financial Condition The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of June 30, 2022, the Company had cash and cash equivalents of $83.2 million. Based on the Company’s current cash balance and its ability to control discretionary spending, such as royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these condensed consolidated financial statements are issued. |
Basis of Presentation and Signi
Basis of Presentation and Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2022 | |
Basis of Presentation and Significant Accounting Policies | |
Basis of Presentation and Significant Accounting Policies | 2. Basis of Presentation and Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with GAAP in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. As permitted under those rules certain footnotes or other financial information can be condensed or omitted. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 8, 2022. These financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full year. Use of Estimates The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company’s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported. The COVID-19 pandemic has resulted in a global slowdown of economic activity which has led to delays and could result in further delays or terminations of some clinical trials underlying the Company’s RPAs. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements. Cash, Cash Equivalents and Restricted Cash Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of June 30, 2022, the Company had cash equivalent balances of $30.0 million, defined as highly liquid financial instruments purchased with original maturities of three months or less. The Company considers all highly liquid debt instruments with maturities of three months or less at the time the Company acquires them and that can be liquidated without prior notice or penalty to be cash equivalents. As of December 31, 2021, the Company did not have any cash equivalent balances. Restricted cash as of December 31, 2021 consisted of bank deposits held to pay dividends on the Company’s Series A and Series B Preferred Stock. As of June 30, 2022, the Company has paid the first year of dividends for the Series A and Series B Preferred stock and is no longer required to hold a restricted cash balance. The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to such cash. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands): June 30, December 31, 2022 2021 Cash and cash equivalents $ 83,182 $ 93,328 Restricted cash — 2,049 Total cash, cash equivalents and restricted cash $ 83,182 $ 95,377 Revenue Recognition The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied. The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products. License of intellectual property If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time). Milestone payments At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. Royalties For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. Sale of Future Revenue Streams The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment. Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company’s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period. Stock-Based Compensation The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. Equity Securities The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive loss at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations and comprehensive loss in the period of sale. Purchase of Rights to Future Milestones, Royalties and Commercial Payments The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the condensed consolidated statement of operations and comprehensive loss. The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent or current based on whether payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue. The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty receivable asset. If an impairment indicator is identified, and the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of June 30, 2022 and December 31, 2021. Leases The Company leases its headquarters office space in Emeryville, California. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length. Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred. Income Taxes The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable. The recognition, derecognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at each reporting date. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits. Net Loss per Share Attributable to Common Stockholders The Company calculates basic and diluted loss per share attributable to common stockholders using the two-class method. The Company’s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company’s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities. Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period and any deemed dividends related to beneficial conversion features on convertible preferred stock, if applicable, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net loss per share attributable to common stockholders is then calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding. Diluted net loss per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock. The calculation of diluted net loss per share attributable to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options or warrants, the presumed exercise of such securities is dilutive to net loss per share attributable to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company’s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company’s share price and, therefore, are not included in the diluted shares until the contingency is resolved. Concentration of Risk Cash, cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. For the three months ended June 30, 2022, two partners represented 51% and 47% of total revenues. For the six months ended June 30, 2022, four partners represented 49%, 20%, 18% and 12% of total revenues. For the three months ended June 30, 2021, two partners represented 55% and 42% of total revenues. For the six months ended June 30, 2021, two partners represented 57% and 39% of total revenues. As of December 31, 2021, one partner represented 100% of the trade receivables, net balance. As of June 30, 2022, the Company had no trade receivables, net balance. Comprehensive Loss Comprehensive loss is comprised of two components: net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity but are excluded from net loss. The Company did not record any transactions within other comprehensive loss in the periods presented and, therefore, the net loss and comprehensive loss were the same for all periods presented. Accounting Pronouncements Recently Adopted In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company adopted ASU 2021-04 and related updates on January 1, 2022. The adoption of ASU 2021-04 had no impact on the condensed consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments |
Condensed Consolidated Financia
Condensed Consolidated Financial Statement Detail | 6 Months Ended |
Jun. 30, 2022 | |
Condensed Consolidated Financial Statement Detail | |
Condensed Consolidated Financial Statement Detail | 3. Condensed Consolidated Financial Statements Details Equity Securities As of June 30, 2022 and December 31, 2021, equity securities consisted of an investment in Rezolute’s common stock of $0.5 million and $0.8 million, respectively (Note 4). For the three and six months ended June 30, 2022, the Company recognized a loss of $25,000 and $0.3 million, respectively, due to the change in fair value of its investment in Rezolute’s common stock in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive loss. For the three and six months ended June 30, 2021, the Company recognized a gain of $1.3 million and $0.6 million, respectively, due to the change in fair value of its investment. Accrued and Other Liabilities Accrued and other liabilities consisted of the following (in thousands): June 30, December 31, 2022 2021 Accrued incentive compensation 461 55 Accrued legal and accounting fees 424 295 Accrued payroll and benefits 121 135 Other accrued liabilities 20 40 Total $ 1,026 $ 525 Net Loss Per Share Attributable to Common Stockholders The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator Net loss $ (4,670) $ (2,237) $ (6,950) $ (9,610) Less: Series A accumulated dividends (530) (530) (1,061) (1,061) Less: Series B accumulated dividends (838) (763) (1,675) (763) Net loss attributable to common stockholders, basic and diluted $ (6,038) $ (3,530) $ (9,686) $ (11,434) Denominator Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders 11,421 11,285 11,376 11,263 Basic and diluted net loss per share attributable to common stockholders $ (0.53) (0.31) $ (0.85) $ (1.02) Potentially dilutive securities are excluded from the calculation of diluted net loss per share attributable to common stockholders if their inclusion is anti-dilutive. The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Convertible preferred stock 5,003 5,003 5,003 5,003 Common stock options 889 377 813 318 Warrants for common stock 6 5 6 5 Total 5,898 5,385 5,822 5,326 |
Licensing and Other Arrangement
Licensing and Other Arrangements | 6 Months Ended |
Jun. 30, 2022 | |
Licensing and Other Arrangements | |
Licensing and Other Arrangements | 4. Licensing and Other Arrangements Novartis – Anti-TGFβ Antibody (NIS793) On September 30, 2015, the Company and Novartis entered into the Anti-TGFβ Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company’s anti-transforming growth factor beta (“TGFβ”) antibody program (now “NIS793”). Under the terms of the Anti-TGFβ Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGFβ Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’ royalty obligations end. The Anti-TGFβ Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGFβ Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on one hundred eighty days’ notice. The Company concluded that there were multiple promised goods and services under the Anti-TGFβ Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December 31, 2015. The Company was eligible to receive up to a total of $480.0 million in development, regulatory and commercial milestones under the Anti-TGFβ Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGFβ Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment which was recognized as license fees in the consolidated statement of operations and comprehensive income. The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’ performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid single-digit percentage rate to up to a low double-digit percentage rate. Novartis’ obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country. On October 21, 2020, the Company earned a $25.0 million milestone upon the dosing of the first patient in Novartis’ first NIS793 Phase 2 clinical trial. As specified under the terms of the Anti-TGFβ Antibody License Agreement, the Company received $17.7 million in cash, and the remaining balance of $7.3 million was recognized as a reduction to the Company's debt obligation to Novartis. On October 20, 2021, the Company earned a $35.0 million milestone payment upon dosing of the first patient in Novartis’ first NIS793 Phase 3 clinical trial. The Company is eligible to receive remaining milestones up to a total of $410.0 million under the Anti-TGFβ Antibody License Agreement. As of June 30, 2022 and December 31, 2021, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized for the three and six months ended June 30, 2022 and 2021. Novartis – Anti-IL-1β Antibody (VPM087) and IL-1 Beta On August 24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (“VPM087”), a novel anti-Interleukin-1 (“IL-1”) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087. On August 24, 2017, pursuant to a separate agreement (the “IL-1 Target License Agreement”), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the “Exclusivity Option”) to such intellectual property for the treatment and prevention of cardiovascular disease. Under the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to €12.0 million) was paid by Novartis, on behalf of the Company, to settle the Company’s outstanding debt with Les Laboratories Servier (“Servier”) (the “Servier Loan”). In addition, Novartis extended the maturity date on the Company’s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company’s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August 24, 2017, resulting in a $0.2 million premium paid to the Company. Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company’s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid single-digits. Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’ royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six months’ prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point. At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the year ended December 31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority. The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’ performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. As of June 30, 2022 and December 31, 2021, there were no contract assets or contract liabilities related to this arrangement, and none of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized for the three and six months ended June 30, 2022 and 2021. Takeda On November 1, 2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda. Under the terms of the Takeda Collaboration Agreement, the Company may receive additional milestone payments aggregating up to $19.0 million relating to TAK-079 (mezagitamab) and TAK-169, and low single-digit royalties on future sales of all products subject to this license. The Company’s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company’s right to royalties expires on the later of 13.5 years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration). In February 2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company’s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company’s right to royalties expires on the later of 10 years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent. On November 16, 2020, the first patient was dosed in Takeda’s Phase 2 study of mezagitamab, and the Company earned a $2.0 million milestone payment from Takeda. No revenue was recognized for the three months ended June 30, 2022. The Company earned a development milestone pursuant to the Takeda Collaboration Agreement and recognized $0.8 million as revenue from contracts with customers in the condensed consolidated statement of operations and comprehensive loss for the six months ended June 30, 2022. No revenue was recognized for the three and six months ended June 30, 2021. As of June 30, 2022 and December 31, 2021, there were no contract assets or contract liabilities related to this arrangement, and none of the costs to obtain or fulfill the contract were capitalized. The Company is eligible to receive remaining milestones up to a total of $16.0 million under the Takeda Collaboration Agreement. Rezolute On December 6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now “RZ358”) products for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities. Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $232.0 million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid teens based upon annual net sales of any commercial product incorporating RZ358. The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute’s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. Rezolute is obligated to take customary steps to advance RZ358, including using diligent efforts to commence the next clinical study for RZ358 by a certain deadline and to meet certain spending requirements on an annual basis for the program until a marketing approval application for RZ358 is accepted by the FDA. Rezolute’s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country. Rezolute’s future royalty obligations in the United States will be reduced by 20% if the manufacture, use or sale of a licensed product is not covered by a valid XOMA patent claim, until such a claim is issued. Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute’s other non-RZ358 products from its current programs, including RZ402 which is in Phase 1 clinical testing. Rezolute’s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of twelve years from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that any such licensee royalty will terminate upon the termination of the licensee’s obligation to make payments to Rezolute based on sales of such product in such country The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days’ notice at any time. To the extent permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents. No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute’s financing activities. The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezolute’s financing and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezolute’s common stock (as adjusted for the 1 In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to XOMA pursuant to the Rezolute License Agreement. The Company recognized no revenue and $2.0 million as revenue from contracts with customers in the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2022, respectively. No revenue was recognized for the three and six months ended June 30, 2021. As of June 30, 2022 and December 31, 2021, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. Janssen Biotech The Company and Janssen were parties to a license agreement which was terminated in 2017. year-and-sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties. The Company concluded that the new agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2019 as it had completed its performance obligation. The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen’s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. In May 2021, the Company earned a $0.5 million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen’s biologic assets. In December 2021, the Company earned a $0.2 million milestone pursuant to its agreement with Janssen. As of June 30, 2022 and December 31, 2021, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized for the three and six months ended June 30, 2022. The Company recognized milestone revenue of $0.5 million for the three and six months ended June 30, 2021. Affimed In April 2021, the Company and Affimed entered into a contractual agreement, under which the Company is eligible to receive payments from Affimed on potential future commercial sales related to three ICE The Company concluded that the commercial milestone payments are solely dependent on Affimed’s performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the commercial milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related approvals occur and therefore have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. As of June 30, 2022 and December 31, 2021, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized for the three and six months ended June 30, 2022. No revenue was recognized for the three and six months ended June 30, 2021. Sale of Future Revenue Streams On December 21, 2016, the Company entered into two royalty interest sale agreements (together, the “Royalty Sale Agreements”) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August 18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in December 2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October 27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million. The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under the units-of-revenue method over the life of the license agreements because of the Company’s limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company’s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP, and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under the units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements and then applying that ratio to the period’s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product. The Company recognized $0.5 million and $0.8 million as revenue under the units-of-revenue method under these arrangements during the three and six months ended June 30, 2022, respectively. The Company recognized $0.4 million and $0.7 million as revenue under the units-of-revenue method under these arrangements during the three and six months ended June 30, 2021, respectively. As of June 30, 2022, the Company classified $1.7 million and $10.8 million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively. As of December 31, 2021, the Company classified $1.6 million and $11.7 million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively. |
Royalty and Commercial Payment
Royalty and Commercial Payment Purchase Agreements | 6 Months Ended |
Jun. 30, 2022 | |
Royalty and Commercial Payment Purchase Agreements | |
Royalty and Commercial Payment Purchase Agreements | 5. Royalty and Commercial Payment Purchase Agreements The balance of long-term royalty and commercial payment receivables was $66.6 million and $69.1 million as of June 30, 2022 and December 31, 2021, respectively. The balance of short-term royalty and commercial payment receivables was $2.5 million as of June 30, 2022. There were no short-term royalty and commercial payment receivables as of December 31, 2021. There were no acquisitions of royalty rights, commercial payment rights or cash receipts Royalty Purchase Agreement with Agenus On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. (“Incyte”) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestones related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid teens-digit percentage of applicable net sales. In addition, the Company acquired the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product currently in clinical development, due to Agenus from Merck and 10% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company’s share in future potential development, regulatory and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements. Under the terms of the Agenus RPA, the Company paid Agenus $15.0 million. At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the consolidated balance sheets. In November 2020, MK-4830 advanced into Phase 2 development, and Agenus earned a $10.0 million clinical development milestone under its license agreement with Merck, of which the Company earned $1.0 million. In accordance with the cost recovery method, the $1.0 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance. The Company continues to assess that no further payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its quarterly impairment assessment, and no impairment indicators were identified. Accordingly, no impairment was recorded as of June 30, 2022 or December 31, 2021. Royalty Purchase Agreement with Bioasis On February 25, 2019, the Company entered into the Bioasis RPA, pursuant to which the Company acquired potential future milestone and royalty rights from Bioasis for product candidates that are being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. In addition, the Company was granted options to purchase a 1% royalty right on the next two license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on the purchase of royalty rights on subsequent Bioasis license agreements with third parties. Upon exercise of the option related to the second license agreement executed by Bioasis, the Company may be obligated to pay up to $0.3 million per licensed product. Upon exercise of the option related to the third license agreement executed by Bioasis, the Company may be obligated to pay up to $0.4 million per licensed product. Under the terms of the Bioasis RPA, the Company paid $0.3 million and will make contingent future cash payments of up to $0.2 million to Bioasis as the licensed product candidates reach certain development milestones (the “Bioasis Contingent Consideration”). At the inception of the agreement, the Company recorded $0.4 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Bioasis Contingent Consideration of $0.1 million. Future changes in the estimated fair value of the contingent consideration will be recognized in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive income. As of June 30, 2022, there was no change in the fair value of the contingent consideration from its initial value and no amounts were paid during the three and six months ended June 30, 2022. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its quarterly impairment assessment, and no impairment indicators were identified. Accordingly, no impairment was recorded as of June 30, 2022 or December 31, 2021. On November 2, 2020, the Company entered into the Second Bioasis RPA, pursuant to which the Company acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that are being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. The Company paid Bioasis $1.2 million upon closing of the Second Bioasis RPA for the purchased rights. At the inception of the Second Bioasis RPA, the Company recorded $1.2 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under the Second Bioasis RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and other payments until the purchase price has been fully collected. The Company performed its quarterly impairment assessment, and no impairment indicators were identified. Accordingly, no impairment was recorded as of June 30, 2022 or December 31, 2021. Royalty Purchase Agreement with Aronora On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone, and option payments (the “Non-Royalties”) related to five anti-thrombotic hematology drug candidates. Three candidates were subject to Aronora’s collaboration with Bayer (the “Bayer Products”), including one which was subject to an exclusive license option by Bayer. The Company will receive 100% of future royalties and 10% of future Non-Royalties economics from these Bayer Products. The other two candidates are unpartnered (the “non-Bayer Products”) for which the Company will receive low single-digit percentage of net sales and 10% of Non-Royalties. The future payment percentage for Non-Royalties will be reduced from 10% to 5% upon the Company’s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products. Under the terms of the Aronora RPA, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB (Note 8). The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September 1, 2019 (up to a total of $3.0 million, the “Aronora Contingent Consideration”). Pursuant to the Aronora RPA, if the Company receives $250.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the “Royalty Milestones”). The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product. Royalties per product in excess of $250.0 million are retained by the Company. At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September 2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its quarterly impairment assessment, and no impairment indicators were identified. Accordingly, no impairment was recorded as of June 30, 2022 or December 31, 2021. Royalty Purchase Agreement with Palobiofarma On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin’s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the “Palo Licensed Products”) that are being developed by Palo. Novartis is a development partner on NIR178, one of the Palo Licensed Products, and NIR178 is being developed pursuant to a license agreement between Palo and Novartis. Under the terms of the Palo RPA, the Company paid Palo a $10.0 million payment at the close of the transaction, which occurred simultaneously upon parties’ entry into the Palo RPA on September 26, 2019. At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. The Company performed its quarterly impairment assessment, and no impairment indicators were identified. Accordingly, no impairment was recorded as of June 30, 2022 or December 31, 2021. Royalty Purchase Agreement with Viracta On March 22, 2021, the Company entered into the Viracta RPA, pursuant to which the Company acquired the right to receive future royalties, milestones, and other payments related to two clinical-stage drug candidates for $13.5 million. The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (topoisomerase II inhibitor), is being developed by Denovo Biopharma. The Company acquired the right to receive (i) up to $54.0 million in potential milestones, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $20.0 million consideration retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved. At the inception of the Viracta RPA, the Company recorded $13.5 million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under the Viracta RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. The Company performed its quarterly impairment assessment, and no impairment indicators were identified. Accordingly, no impairment was recorded as of June 30, 2022 or December 31, 2021. Royalty Purchase Agreement with Kuros On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals’ vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. The Company may pay up to an additional $142.5 million to Kuros in sales-based milestones. At the inception of the Kuros RPA, the Company recorded $7.0 million as long-term royalty receivables in its consolidated balance sheet. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals resulting in a $5.0 million milestone payment to Kuros. Pursuant to the Kuros RPA, XOMA is entitled to 50% of the milestone payment, which was received by XOMA on July 5, 2022. The Company reclassified $2.5 million of royalty and commercial payment receivables from long-term to short-term in the condensed consolidated balance sheet as of June 30, 2022. The Company performed its quarterly impairment assessment, and no impairment indicators were identified. Accordingly, no impairment was recorded as of June 30, 2022 or December 31, 2021. Commercial Payment Purchase Agreement with Affitech On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche’s faricimab from Affitech for an upfront payment of $6.0 million. The Company is eligible to receive 0.50% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. The Company may pay up to an additional $20.0 million based on the achievement of certain regulatory and sales milestones (Note 15). At the inception of the Affitech CPPA, the Company recorded $14.0 million as long-term royalty receivables which includes the $6.0 million upfront payment and $8.0 million in regulatory milestones in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $8.0 million meet the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of $12.0 million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable. On January 28, 2022, Genentech, a member of the Roche group, received approval from the FDA to commercialize faricimab (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. Roche launched faricimab-svoa during the quarter ended March 31, 2022. The Company is eligible to receive a 0.5% commercial payment stream on net sales associated with faricimab for a ten-year period following its first commercial sale in the United States. Based upon limited available information the Company is unable to reasonably estimate net sales during the three and six months ended June 30, 2022. The Company acquired this interest under the Affitech CPPA, pursuant to which the Company paid Affitech a $5.0 million milestone tied to these U.S. marketing approvals. The Company may pay up to an additional $3.0 million to Affitech based on the achievement of certain regulatory approval milestones and $12.0 million based on the achievement of sales-based milestones. Under the cost recovery method, the Company does not expect to recognize any income related to future commercial payment receipts until the purchase price has been fully collected. The Company performed its quarterly impairment assessment, and no impairment indicators were identified. Accordingly, no impairment was recorded as of June 30, 2022 or December 31, 2021. The following table summarizes the royalty receivable activities during the six months ended June 30, 2022 (in thousands): Short-Term Long-Term Balance at December 31, 2021 $ — $ 69,075 Reclassification to short-term royalty and commercial payment receivable 2,500 (2,500) Balance at June 30, 2022 $ 2,500 $ 66,575 |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Jun. 30, 2022 | |
Fair Value Measurements | |
Fair Value Measurements | 6. Fair Value Measurements The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company’s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions. The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): Fair Value Measurements at June 30, 2022 Using: Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Assets: Cash equivalents: Money market funds $ 10,054 $ — $ — $ 10,054 US treasury bills 19,975 — — 19,975 Total cash equivalents 30,029 — — 30,029 Equity securities 523 — — 523 Total financial assets $ 30,552 $ — $ — $ 30,552 Liabilities: Contingent consideration under RPAs and CPPAs $ — $ — $ 3,075 $ 3,075 Fair Value Measurements at December 31, 2021 Using: Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Assets: Equity securities $ 774 $ — $ — $ 774 Liabilities: Contingent consideration under RPAs and CPPAs $ — $ — $ 8,075 $ 8,075 During the three and six months ended June 30, 2022, there were no transfers between levels. Equity Securities The equity securities consisted of an investment in Rezolute’s common stock and are classified on the condensed consolidated balance sheets as current assets as of June 30, 2022 and December 31, 2021. The equity securities are revalued each reporting period with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive loss. As of June 30, 2022 and December 31, 2021, the Company valued the equity securities using the closing price for Rezolute’s common stock traded on the Nasdaq Stock Market of $3.23 and $4.78, respectively. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement. Contingent Consideration The estimated fair value of the contingent consideration liability at the inception of the Bioasis RPA represents the future consideration that is contingent upon the achievement of specified development milestones for a product candidate. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each licensed product candidate. The estimated fair value of the contingent consideration liability at the inception of the Affitech CPPA represents the future consideration that is contingent upon the achievement of specified regulatory milestones. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving regulatory milestones. Changes in the fair value of the liability for contingent consideration will be recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive loss until settlement. As of June 30, 2022, there were no changes in the estimated fair value of the contingent consideration recorded pursuant to the Bioasis RPA from the initial value of $0.1 million. There were no changes in the estimated fair value of the contingent consideration recorded pursuant to the Affitech CPPA during the three months ended June 30, 2022. During the six months ended June 30, 2022, the estimated fair value of the contingent consideration recorded pursuant to the Affitech CPPA decreased from $8.0 million to $3.0 million after the Company paid Affitech a total of $5.0 million for milestones tied to the achievement of U.S. marketing approvals in January 2022. |
Lease Agreement
Lease Agreement | 6 Months Ended |
Jun. 30, 2022 | |
Lease Agreement | |
Lease Agreement | 7. Lease Agreements The Company leases one facility in Emeryville, California under an operating lease that expires in February 2023. The Emeryville lease contains an option to extend the lease for an additional term, however, the Company is not reasonably certain to exercise this option. The following table summarizes maturity of the Company’s operating lease liabilities as of June 30, 2022 (in thousands): Operating Undiscounted lease payments Leases 2022 (excluding the six months ended June 30, 2022) 101 2023 34 Total undiscounted lease payments 135 Present value adjustment (2) Total net lease liabilities $ 133 The following table summarizes the cost components of the Company’s operating leases for the three and six months ended June 30, 2022 and 2021 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Lease costs: Operating lease cost $ 44 $ 44 $ 88 $ 88 Variable lease cost (1) 2 2 5 5 Total lease costs $ 46 $ 46 $ 93 $ 93 (1) The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands): Six Months Ended June 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows under operating leases $ 101 $ 98 The present value assumptions used in calculating the present value of the lease payments as of June 30, 2022 and December 31, 2021 were as follows: June 30, December 31, 2022 2021 Weighted-average remaining lease term 0.67 years 1.17 years Weighted-average discount rate 5.51 % 5.51 % |
Common Stock Warrants
Common Stock Warrants | 6 Months Ended |
Jun. 30, 2022 | |
Common Stock Warrants | |
Common Stock Warrants | 8. Common Stock Warrants As of June 30, 2022 and December 31, 2021, the following common stock warrants were outstanding: Exercise Price June 30, December 31, Issuance Date Expiration Date Balance Sheet Classification per Share 2022 2021 May 2018 May 2028 Stockholders’ equity $ 23.69 6,332 6,332 March 2019 March 2029 Stockholders’ equity $ 14.71 4,845 4,845 11,177 11,177 |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2022 | |
Commitments and Contingencies | |
Commitments and Contingencies | 9. Commitments and Contingencies Collaborative Agreements, Royalties and Milestone Payments The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company’s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestone events) have not been recorded on the accompanying condensed consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. Contingent Consideration Pursuant to the Company’s RPAs and CPPAs with Bioasis, Aronora, Kuros and Affitech, the Company has committed to pay the Bioasis Contingent Consideration, the Aronora Royalty Milestones, the Kuros Sales Milestones and the Affitech regulatory and sales milestones. As of June 30, 2022, the estimated fair value of the Bioasis Contingent Consideration is $0.1 million and the estimated fair value of the Affitech Regulatory Milestones is $3.0 million (Note 6). The liability for future Aronora Royalty Milestones, Kuros Sales Milestones and Affitech Sales Milestones will be recorded when the amounts, by product, are estimable and probable. As of June 30, 2022, none of these Aronora Royalty Milestones, Kuros |
Stock Based Compensation
Stock Based Compensation | 6 Months Ended |
Jun. 30, 2022 | |
Stock Based Compensation | |
Stock-based Compensation | 10. Stock Based Compensation The Company may grant qualified and non-qualified stock options, common stock and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company’s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. Stock Options Stock options generally vest monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement. The fair value of the stock options granted during the three and six months ended June 30, 2022 and 2021, was estimated based on the following weighted average assumptions: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Dividend yield 0 % 0 % 0 % 0 % Expected volatility 69 % 76 % 70 % 94 % Risk-free interest rate 2.90 % 1.06 % 2.17 % 0.77 % Expected term 5.61 years 6.00 years 5.65 years 5.68 years Stock option activity for the six months ended June 30, 2022, was as follows: Weighted Weighted Average Average Aggregate Exercise Contractual Intrinsic Number of Price Term Value shares Per Share (in years) (in thousands) Outstanding at January 1, 2022 1,911,177 $ 20.64 6.33 $ 15,103 Granted 222,972 19.83 Exercised (101,811) 8.07 Forfeited, expired or cancelled (7,447) 31.04 Outstanding at June 30, 2022 2,024,891 $ 21.15 6.31 $ 16,048 Exercisable at June 30, 2022 1,571,458 $ 19.94 5.47 $ 15,414 The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2022 and 2021 was $2.1 million and $1.5 million, respectively. The weighted-average grant-date fair value per share of the options granted during the six months ended June 30, 2022 and 2021 was $12.21 and $27.89, respectively. As of June 30, 2022, $5.0 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 2.11 years. Stock-based Compensation Expense The following table shows total stock-based compensation expense for stock options and ESPP in the condensed consolidated statements of operations and comprehensive loss (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 General and administrative 837 768 1,815 3,666 Total stock-based compensation expense $ 837 $ 768 $ 1,815 $ 3,666 In April 2022, the Company entered into a letter agreement with Thomas Burns that amends and supplements his amended and restated employment agreement. Pursuant to the letter agreement, in the event Mr. Burns remains employed by the Company for a twelve-month period following the first day of employment of the Company’s new Chief Executive Officer, he will be deemed “retirement eligible” for purposes of his equity awards under the terms of his equity award agreements. Conditioned on his execution of a release in favor of the Company, Mr. Burns will also receive this benefit upon any involuntary termination for reasons other than cause. |
Capital Stock
Capital Stock | 6 Months Ended |
Jun. 30, 2022 | |
Capital Stock | |
Capital Stock | 11. Capital Stock Dividends During the six months ended June 30, 2022, the Company’s Board of Directors declared and paid cash dividends on the Company’s Series A Preferred Stock and Series B Depositary shares as follows: Series A Preferred Stock Series B Depositary Share Cash Dividend Declared Cash Dividend Declared Dividend Declaration Date ($ per share) ($ per share) Dividend Payment Date October 20, 2021 $ 0.53906 $ 0.52344 January 18, 2022 March 17, 2022 $ 0.53906 $ 0.52344 April 15, 2022 May 18, 2022 $ 0.53906 $ 0.52344 July 15, 2022 BVF Ownership As of June 30, 2022, BVF owned approximately 30.9% of the Company’s total outstanding shares of common stock, and if all the Series X convertible preferred shares were converted, BVF would own 51.9% of the Company’s total outstanding shares of common stock. The Company’s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of June 30, 2022, the contingency was not met, therefore the Series A Preferred Stock is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company. 2018 Common Stock ATM Agreement On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $50.0 million. No shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed. 2021 Series B Preferred Stock ATM Agreement On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $50.0 million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to 3% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. No shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed. |
Income Taxes
Income Taxes | 6 Months Ended |
Jun. 30, 2022 | |
Income Taxes | |
Income Taxes | 12. Income Taxes No provision was made for federal income tax, since the Company has incurred net operating losses during the three and six months ended June 30, 2022 and 2021. The Company continues to maintain a full valuation allowance against its remaining net deferred tax assets. The Company has a total of $5.9 million of gross unrecognized tax benefits, none of which would affect the effective tax rate upon realization as it currently has a full valuation allowance against its net deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future. The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through June 30, 2022, the Company has not accrued interest or penalties related to uncertain tax positions. |
Basis of Presentation and Sig_2
Basis of Presentation and Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2022 | |
Basis of Presentation and Significant Accounting Policies | |
Basis of Presentation | Basis of Presentation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with GAAP in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. As permitted under those rules certain footnotes or other financial information can be condensed or omitted. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 8, 2022. These financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full year. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company’s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported. The COVID-19 pandemic has resulted in a global slowdown of economic activity which has led to delays and could result in further delays or terminations of some clinical trials underlying the Company’s RPAs. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements. |
Cash, Cash Equivalents and Restricted Cash | Cash, Cash Equivalents and Restricted Cash Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of June 30, 2022, the Company had cash equivalent balances of $30.0 million, defined as highly liquid financial instruments purchased with original maturities of three months or less. The Company considers all highly liquid debt instruments with maturities of three months or less at the time the Company acquires them and that can be liquidated without prior notice or penalty to be cash equivalents. As of December 31, 2021, the Company did not have any cash equivalent balances. Restricted cash as of December 31, 2021 consisted of bank deposits held to pay dividends on the Company’s Series A and Series B Preferred Stock. As of June 30, 2022, the Company has paid the first year of dividends for the Series A and Series B Preferred stock and is no longer required to hold a restricted cash balance. The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to such cash. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands): June 30, December 31, 2022 2021 Cash and cash equivalents $ 83,182 $ 93,328 Restricted cash — 2,049 Total cash, cash equivalents and restricted cash $ 83,182 $ 95,377 |
Revenue Recognition | Revenue Recognition The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied. The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products. License of intellectual property If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time). Milestone payments At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. Royalties For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. |
Sale of Future Revenue Streams | Sale of Future Revenue Streams The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment. Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company’s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period. |
Stock-Based Compensation | Stock-Based Compensation The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. |
Equity Securities | Equity Securities The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive loss at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations and comprehensive loss in the period of sale. |
Purchase of Rights to Future Milestones, Royalties and Commercial Payments | Purchase of Rights to Future Milestones, Royalties and Commercial Payments The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the condensed consolidated statement of operations and comprehensive loss. The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent or current based on whether payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue. The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty receivable asset. If an impairment indicator is identified, and the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of June 30, 2022 and December 31, 2021. |
Leases | Leases The Company leases its headquarters office space in Emeryville, California. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length. Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred. |
Income Taxes | Income Taxes The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable. The recognition, derecognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at each reporting date. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits. |
Net Loss per Share Attributable to Common Stockholders | Net Loss per Share Attributable to Common Stockholders The Company calculates basic and diluted loss per share attributable to common stockholders using the two-class method. The Company’s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company’s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities. Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period and any deemed dividends related to beneficial conversion features on convertible preferred stock, if applicable, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net loss per share attributable to common stockholders is then calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding. Diluted net loss per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock. The calculation of diluted net loss per share attributable to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options or warrants, the presumed exercise of such securities is dilutive to net loss per share attributable to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company’s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company’s share price and, therefore, are not included in the diluted shares until the contingency is resolved. |
Concentration of Risk | Concentration of Risk Cash, cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. For the three months ended June 30, 2022, two partners represented 51% and 47% of total revenues. For the six months ended June 30, 2022, four partners represented 49%, 20%, 18% and 12% of total revenues. For the three months ended June 30, 2021, two partners represented 55% and 42% of total revenues. For the six months ended June 30, 2021, two partners represented 57% and 39% of total revenues. As of December 31, 2021, one partner represented 100% of the trade receivables, net balance. As of June 30, 2022, the Company had no trade receivables, net balance. |
Comprehensive Loss | Comprehensive Loss Comprehensive loss is comprised of two components: net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity but are excluded from net loss. The Company did not record any transactions within other comprehensive loss in the periods presented and, therefore, the net loss and comprehensive loss were the same for all periods presented. |
Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements | Accounting Pronouncements Recently Adopted In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company adopted ASU 2021-04 and related updates on January 1, 2022. The adoption of ASU 2021-04 had no impact on the condensed consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments |
Basis of Presentation and Sig_3
Basis of Presentation and Significant Accounting Policies (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Basis of Presentation and Significant Accounting Policies | |
Schedule of of cash and cash equivalents and restricted cash | The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands): June 30, December 31, 2022 2021 Cash and cash equivalents $ 83,182 $ 93,328 Restricted cash — 2,049 Total cash, cash equivalents and restricted cash $ 83,182 $ 95,377 |
Condensed Consolidated Financ_2
Condensed Consolidated Financial Statement Detail (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Consolidated Financial Statements | |
Accrued and Other Liabilities | Accrued and other liabilities consisted of the following (in thousands): June 30, December 31, 2022 2021 Accrued incentive compensation 461 55 Accrued legal and accounting fees 424 295 Accrued payroll and benefits 121 135 Other accrued liabilities 20 40 Total $ 1,026 $ 525 |
Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net (Loss) per Share Available to Common Stockholders | The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator Net loss $ (4,670) $ (2,237) $ (6,950) $ (9,610) Less: Series A accumulated dividends (530) (530) (1,061) (1,061) Less: Series B accumulated dividends (838) (763) (1,675) (763) Net loss attributable to common stockholders, basic and diluted $ (6,038) $ (3,530) $ (9,686) $ (11,434) Denominator Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders 11,421 11,285 11,376 11,263 Basic and diluted net loss per share attributable to common stockholders $ (0.53) (0.31) $ (0.85) $ (1.02) |
Outstanding Securities Considered Anti-Dilutive | The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Convertible preferred stock 5,003 5,003 5,003 5,003 Common stock options 889 377 813 318 Warrants for common stock 6 5 6 5 Total 5,898 5,385 5,822 5,326 |
Royalty and Commercial Paymen_2
Royalty and Commercial Payment Purchase Agreements (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Royalty and Commercial Payment Purchase Agreements | |
Summary of royalty receivable activities | The following table summarizes the royalty receivable activities during the six months ended June 30, 2022 (in thousands): Short-Term Long-Term Balance at December 31, 2021 $ — $ 69,075 Reclassification to short-term royalty and commercial payment receivable 2,500 (2,500) Balance at June 30, 2022 $ 2,500 $ 66,575 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Fair Value Measurements | |
Schedule of Financial Assets and Liabilities Carried at Fair Value on Recurring Basis | The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): Fair Value Measurements at June 30, 2022 Using: Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Assets: Cash equivalents: Money market funds $ 10,054 $ — $ — $ 10,054 US treasury bills 19,975 — — 19,975 Total cash equivalents 30,029 — — 30,029 Equity securities 523 — — 523 Total financial assets $ 30,552 $ — $ — $ 30,552 Liabilities: Contingent consideration under RPAs and CPPAs $ — $ — $ 3,075 $ 3,075 Fair Value Measurements at December 31, 2021 Using: Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Assets: Equity securities $ 774 $ — $ — $ 774 Liabilities: Contingent consideration under RPAs and CPPAs $ — $ — $ 8,075 $ 8,075 |
Lease Agreement (Tables)
Lease Agreement (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Lease Agreement | |
Schedule of maturity of operating lease liabilities | The following table summarizes maturity of the Company’s operating lease liabilities as of June 30, 2022 (in thousands): Operating Undiscounted lease payments Leases 2022 (excluding the six months ended June 30, 2022) 101 2023 34 Total undiscounted lease payments 135 Present value adjustment (2) Total net lease liabilities $ 133 |
Schedule of cost components of operating leases | The following table summarizes the cost components of the Company’s operating leases for the three and six months ended June 30, 2022 and 2021 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Lease costs: Operating lease cost $ 44 $ 44 $ 88 $ 88 Variable lease cost (1) 2 2 5 5 Total lease costs $ 46 $ 46 $ 93 $ 93 |
Summary of supplemental cash flow information related to operating leases | Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Lease costs: Operating lease cost $ 44 $ 44 $ 88 $ 88 Variable lease cost (1) 2 2 5 5 Total lease costs $ 46 $ 46 $ 93 $ 93 |
Schedule of present value assumptions used in calculating the present value of lease payments | June 30, December 31, 2022 2021 Weighted-average remaining lease term 0.67 years 1.17 years Weighted-average discount rate 5.51 % 5.51 % |
Common Stock Warrants (Tables)
Common Stock Warrants (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Common Stock Warrants | |
Summary of Common Stock Warrants Outstanding | Exercise Price June 30, December 31, Issuance Date Expiration Date Balance Sheet Classification per Share 2022 2021 May 2018 May 2028 Stockholders’ equity $ 23.69 6,332 6,332 March 2019 March 2029 Stockholders’ equity $ 14.71 4,845 4,845 11,177 11,177 |
Stock Based Compensation (Table
Stock Based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Stock Based Compensation | |
Weighted Average Assumptions | Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Dividend yield 0 % 0 % 0 % 0 % Expected volatility 69 % 76 % 70 % 94 % Risk-free interest rate 2.90 % 1.06 % 2.17 % 0.77 % Expected term 5.61 years 6.00 years 5.65 years 5.68 years |
Stock Option Activity | Weighted Weighted Average Average Aggregate Exercise Contractual Intrinsic Number of Price Term Value shares Per Share (in years) (in thousands) Outstanding at January 1, 2022 1,911,177 $ 20.64 6.33 $ 15,103 Granted 222,972 19.83 Exercised (101,811) 8.07 Forfeited, expired or cancelled (7,447) 31.04 Outstanding at June 30, 2022 2,024,891 $ 21.15 6.31 $ 16,048 Exercisable at June 30, 2022 1,571,458 $ 19.94 5.47 $ 15,414 |
Stock-based Compensation Expense | The following table shows total stock-based compensation expense for stock options and ESPP in the condensed consolidated statements of operations and comprehensive loss (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 General and administrative 837 768 1,815 3,666 Total stock-based compensation expense $ 837 $ 768 $ 1,815 $ 3,666 |
Capital Stock (Tables)
Capital Stock (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Capital Stock | |
Schedule of declared and paid cash dividends | Series A Preferred Stock Series B Depositary Share Cash Dividend Declared Cash Dividend Declared Dividend Declaration Date ($ per share) ($ per share) Dividend Payment Date October 20, 2021 $ 0.53906 $ 0.52344 January 18, 2022 March 17, 2022 $ 0.53906 $ 0.52344 April 15, 2022 May 18, 2022 $ 0.53906 $ 0.52344 July 15, 2022 |
Description of Business - Liqui
Description of Business - Liquidity (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Description of Business | ||
Cash and cash equivalents | $ 83,182 | $ 93,328 |
Basis of Presentation and Sig_4
Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | Dec. 31, 2020 |
Basis of Presentation and Significant Accounting Policies | ||||
Cash equivalents | $ 30,000 | |||
Cash and cash equivalents | 83,182 | $ 93,328 | ||
Restricted cash | 2,049 | |||
Total cash, cash equivalents and restricted cash | $ 83,182 | $ 95,377 | $ 83,785 | $ 86,364 |
Basis of Presentation and Sig_5
Basis of Presentation and Significant Accounting Policies - Purchase of Rights to Future Milestones and Royalties and Income Taxes and Net Income (Loss) per Share (Details) - USD ($) $ in Millions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Purchase of Rights to Future Milestones and Royalties | ||
Impairment of long-term royalty receivable | $ 0 | $ 0 |
Income tax penalties or interest charged | $ 0 |
Basis of Presentation and Sig_6
Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details) $ in Millions | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 USD ($) customer | Jun. 30, 2021 customer | Jun. 30, 2022 USD ($) customer | Jun. 30, 2021 customer | Dec. 31, 2021 customer | |
Concentration of Risk | |||||
Trade receivable, net | $ | $ 0 | $ 0 | |||
Customer Concentration Risk | Revenues. | |||||
Concentration of Risk | |||||
Number of major partners | 2 | 2 | 4 | 2 | |
Customer Concentration Risk | Revenues. | Partner 1 | |||||
Concentration of Risk | |||||
Concentration risk (as a percent) | 51% | 55% | 49% | 57% | |
Customer Concentration Risk | Revenues. | Partner 2 | |||||
Concentration of Risk | |||||
Concentration risk (as a percent) | 47% | 42% | 20% | 39% | |
Customer Concentration Risk | Revenues. | Partner 3 | |||||
Concentration of Risk | |||||
Concentration risk (as a percent) | 18% | ||||
Customer Concentration Risk | Revenues. | Partner 4 | |||||
Concentration of Risk | |||||
Concentration risk (as a percent) | 12% | ||||
Credit Concentration Risk | Trade Receivables | Partner 1 | |||||
Concentration of Risk | |||||
Number of major partners | 1 | ||||
Concentration risk (as a percent) | 100% |
Condensed Consolidated Financ_3
Condensed Consolidated Financial Statement Detail - Equity Securities (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |
Equity Securities | |||||
Gain (loss) recognized due to change in fair value of investment | $ (251) | $ 617 | |||
Rezolute | |||||
Equity Securities | |||||
Long-term equity securities | $ 500 | 500 | $ 800 | ||
Gain (loss) recognized due to change in fair value of investment | $ (25) | $ 1,300 | $ (300) | $ 600 |
Condensed Consolidated Financ_4
Condensed Consolidated Financial Statement Detail - Accrued and Other Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Accrued and other liabilities | ||
Accrued incentive compensation | $ 461 | $ 55 |
Accrued legal and accounting fees | 424 | 295 |
Accrued payroll and benefits | 121 | 135 |
Other accrued liabilities | 20 | 40 |
Total | $ 1,026 | $ 525 |
Condensed Consolidated Financ_5
Condensed Consolidated Financial Statement Detail - Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2022 | Mar. 31, 2022 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Numerator | ||||||
Net loss | $ (4,670) | $ (2,280) | $ (2,237) | $ (7,373) | $ (6,950) | $ (9,610) |
Less: accumulated dividends | (1,368) | (1,293) | (2,736) | (1,824) | ||
Net loss attributable to common stockholders, basic | (6,038) | (3,530) | (9,686) | (11,434) | ||
Net loss attributable to common stockholders, diluted | $ (6,038) | $ (3,530) | $ (9,686) | $ (11,434) | ||
Denominator | ||||||
Weighted average shares used in computing basic net loss per share attributable to common stockholders | 11,421 | 11,285 | 11,376 | 11,263 | ||
Weighted average shares used in computing diluted net loss per share attributable to common stockholders | 11,421 | 11,285 | 11,376 | 11,263 | ||
Basic net loss per share attributable to common stockholders (in dollars per share) | $ (0.53) | $ (0.31) | $ (0.85) | $ (1.02) | ||
Diluted net loss per share attributable to common stockholders (in dollars per share) | $ (0.53) | $ (0.31) | $ (0.85) | $ (1.02) | ||
8.625% Series A Cumulative, Perpetual Preferred Stock | ||||||
Numerator | ||||||
Less: accumulated dividends | $ (530) | $ (530) | $ (1,061) | $ (1,061) | ||
8.375% Series B Cumulative, Perpetual Preferred Stock | ||||||
Numerator | ||||||
Less: accumulated dividends | $ (838) | $ (763) | $ (1,675) | $ (763) |
Condensed Consolidated Financ_6
Condensed Consolidated Financial Statement Detail - Outstanding Securities Considered Anti-Dilutive (Details) - shares shares in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share | ||||
Antidilutive securities excluded from computation of net loss per share (in shares) | 5,898 | 5,385 | 5,822 | 5,326 |
Convertible preferred stock | ||||
Antidilutive Securities Excluded From Computation Of Earnings Per Share | ||||
Antidilutive securities excluded from computation of net loss per share (in shares) | 5,003 | 5,003 | 5,003 | 5,003 |
Stock Options | ||||
Antidilutive Securities Excluded From Computation Of Earnings Per Share | ||||
Antidilutive securities excluded from computation of net loss per share (in shares) | 889 | 377 | 813 | 318 |
Warrants for common stock | ||||
Antidilutive Securities Excluded From Computation Of Earnings Per Share | ||||
Antidilutive securities excluded from computation of net loss per share (in shares) | 6 | 5 | 6 | 5 |
Licensing and Other Arrangeme_2
Licensing and Other Arrangements - Novartis - NIS793 (Details) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||
Oct. 20, 2021 USD ($) | Oct. 21, 2020 USD ($) | Sep. 30, 2015 USD ($) item | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2015 USD ($) | Dec. 31, 2021 USD ($) | |
Licensing and other arrangements | ||||||||||
Revenue from contracts with customers | $ 525 | $ 525 | $ 3,275 | $ 544 | ||||||
Novartis Note | ||||||||||
Licensing and other arrangements | ||||||||||
Reduction in debt obligation | $ 7,300 | |||||||||
Novartis International | License Agreement | ||||||||||
Licensing and other arrangements | ||||||||||
Agreement termination prior written notice period | 180 days | |||||||||
Number of performance obligations | item | 1 | |||||||||
Cash payment received | 17,700 | $ 37,000 | ||||||||
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones | $ 410,000 | $ 480,000 | ||||||||
Revenue from contracts with customers | $ 35,000 | $ 25,000 | 0 | $ 0 | 0 | $ 0 | $ 10,000 | |||
Royalty payment period | 10 years | |||||||||
Contract assets | 0 | 0 | $ 0 | |||||||
Contract liabilities | 0 | 0 | 0 | |||||||
Capitalized contract costs | $ 0 | $ 0 | $ 0 |
Licensing and Other Arrangeme_3
Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details) $ / shares in Units, $ in Thousands, € in Millions | 3 Months Ended | 6 Months Ended | |||||
Aug. 24, 2017 USD ($) item agreement $ / shares shares | Aug. 24, 2017 EUR (€) item agreement shares | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | |
Licensing and other arrangements | |||||||
Revenue from contracts with customers | $ 525 | $ 525 | $ 3,275 | $ 544 | |||
Novartis Pharma AG | Gevokizumab License Agreement and IL-1 Target License Agreement | |||||||
Licensing and other arrangements | |||||||
Transaction price | $ 40,200 | ||||||
Cash payment received | 25,700 | ||||||
License agreement consideration received, repayment of debt | 14,300 | ||||||
Common stock premium | $ 200 | ||||||
Number of license agreements | agreement | 2 | 2 | |||||
Number of arrangements | item | 1 | 1 | |||||
Number of performance obligations | item | 2 | 2 | |||||
Remaining performance obligations | 0 | 0 | |||||
Revenue from contracts with customers | 0 | $ 0 | 0 | $ 0 | |||
Contract assets | 0 | 0 | $ 0 | ||||
Contract liabilities | 0 | 0 | 0 | ||||
Capitalized contract costs | $ 0 | $ 0 | $ 0 | ||||
Novartis Pharma AG | Gevokizumab License Agreement | |||||||
Licensing and other arrangements | |||||||
License agreement consideration received | $ 30,000 | ||||||
Cash payment received | 15,700 | ||||||
License agreement consideration received, repayment of debt | 14,300 | € 12 | |||||
Proceeds from issuance of common stock | 5,000 | ||||||
Common stock premium | 200 | ||||||
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones | $ 438,000 | ||||||
Agreement termination prior written notice period | 6 months | 6 months | |||||
Novartis Pharma AG | Gevokizumab License Agreement | Common Stock | |||||||
Licensing and other arrangements | |||||||
Shares issued (in shares) | shares | 539,131 | 539,131 | |||||
Purchase price (in dollars per share) | $ / shares | $ 9.2742 | ||||||
Issuance of common stock, fair value | $ 4,800 | ||||||
Closing stock price (in dollars per share) | $ / shares | $ 8.93 | ||||||
Novartis Pharma AG | IL-1 Target License Agreement | |||||||
Licensing and other arrangements | |||||||
Cash payment received | $ 10,000 |
Licensing and Other Arrangeme_4
Licensing and Other Arrangements - Takeda (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | |||||
Nov. 16, 2020 | Nov. 01, 2006 | Feb. 28, 2009 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |
Licensing and other arrangements | ||||||||
Revenue from contracts with customers | $ 525 | $ 525 | $ 3,275 | $ 544 | ||||
Takeda | Collaboration Agreement | ||||||||
Licensing and other arrangements | ||||||||
Revenue from contracts with customers | $ 2,000 | 0 | $ 0 | 800 | $ 0 | |||
Contract assets | 0 | 0 | $ 0 | |||||
Contract liabilities | 0 | 0 | 0 | |||||
Capitalized contract costs | 0 | 0 | $ 0 | |||||
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones | $ 16,000 | $ 16,000 | ||||||
Takeda | Collaboration Agreement | TAK-079 | ||||||||
Licensing and other arrangements | ||||||||
Royalty payment period | 13 years 6 months | |||||||
Royalty payment period from the first commercial sale of each royalty-bearing discovery product | 12 years | |||||||
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones | $ 19,000 | |||||||
Takeda | Collaboration Agreement | Other antibodies | ||||||||
Licensing and other arrangements | ||||||||
Maximum eligible milestone payments receivable per discovery product candidate | $ 3,300 | |||||||
Royalty payment period | 10 years |
Licensing and Other Arrangeme_5
Licensing and Other Arrangements - Rezolute (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | 37 Months Ended | |||||
Dec. 06, 2017 USD ($) | Jan. 31, 2022 USD ($) | Oct. 31, 2020 | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2020 USD ($) shares | Dec. 31, 2021 USD ($) | |
Licensing and other arrangements | |||||||||
Revenue recognized | $ 525 | $ 525 | $ 3,275 | $ 544 | |||||
Rezolute | |||||||||
Licensing and other arrangements | |||||||||
Reverse stock split | 0.02 | ||||||||
Rezolute | License Agreement and Common Stock Purchase Agreement | |||||||||
Licensing and other arrangements | |||||||||
Revenue recognized | $ 2,000 | 0 | $ 0 | 2,000 | $ 0 | ||||
Payments received upon achievement of financing activities | $ 6,000 | ||||||||
Installment payments received | $ 8,500 | ||||||||
Number of shares received | shares | 161,861 | ||||||||
Contract assets | 0 | 0 | $ 0 | ||||||
Contract liabilities | 0 | 0 | 0 | ||||||
Capitalized contract costs | $ 0 | $ 0 | $ 0 | ||||||
Rezolute | License Agreement | |||||||||
Licensing and other arrangements | |||||||||
Percentage of decrease in future royalty obligations | 20% | ||||||||
Agreement termination prior written notice period | 90 days | ||||||||
License agreement consideration received | $ 0 | ||||||||
Rezolute | License Agreement, RZ358 | |||||||||
Licensing and other arrangements | |||||||||
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones | $ 232,000 | ||||||||
Royalty payment period | 12 years | ||||||||
Rezolute | License Agreement, Non-RZ358 products | |||||||||
Licensing and other arrangements | |||||||||
Royalty payment period | 12 years |
Licensing and Other Arrangeme_6
Licensing and Other Arrangements - Janssen Biotech (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Dec. 31, 2021 | May 31, 2021 | Aug. 31, 2019 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2019 | |
Licensing and other arrangements | ||||||||
Revenue from contracts with customers | $ 525 | $ 525 | $ 3,275 | $ 544 | ||||
Janssen Biotech Inc. | License Agreement | ||||||||
Licensing and other arrangements | ||||||||
Cash payment received | $ 2,500 | |||||||
Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events | $ 3,000 | |||||||
Percentage of royalty on worldwide net sales of each product upon commercialization | 0.75% | |||||||
Revenue from contracts with customers | $ 200 | $ 500 | 0 | $ 500 | 0 | $ 500 | $ 2,500 | |
Contract assets | 0 | 0 | 0 | |||||
Contract liabilities | 0 | 0 | 0 | |||||
Capitalized contract costs | $ 0 | $ 0 | $ 0 |
Licensing and Other Arrangeme_7
Licensing and Other Arrangements - Affimed (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |
Licensing and other arrangements | |||||
Revenue from contracts with customers | $ 525 | $ 525 | $ 3,275 | $ 544 | |
License Agreement | Affimed | |||||
Licensing and other arrangements | |||||
Contract assets | 0 | 0 | $ 0 | ||
Contract liabilities | 0 | 0 | $ 0 | ||
Capitalized contract costs | 0 | 0 | |||
Revenue from contracts with customers | $ 0 | $ 0 | $ 0 | $ 0 |
Licensing and Other Arrangeme_8
Licensing and Other Arrangements - Sale of Future Revenue Streams (Details) $ in Thousands | 3 Months Ended | 6 Months Ended | ||||
Dec. 21, 2016 USD ($) agreement period | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | |
Licensing and other arrangements | ||||||
Unearned revenue recognized under units-of-revenue method | $ (815) | $ (731) | ||||
Revenue recognized under units-of-revenue method | $ 458 | $ 376 | 815 | 731 | ||
Unearned revenue recognized under units-of-revenue method, current | 1,669 | 1,669 | $ 1,641 | |||
Unearned revenue recognized under units-of-revenue method, noncurrent | 10,842 | 10,842 | 11,685 | |||
HealthCare Royalty Partners II, L.P | ||||||
Licensing and other arrangements | ||||||
Revenue recognized under units-of-revenue method | 500 | $ 400 | 800 | $ 700 | ||
HealthCare Royalty Partners II, L.P | Royalty Sale Agreements | ||||||
Licensing and other arrangements | ||||||
Number of agreements | agreement | 2 | |||||
Unearned revenue recognized under units-of-revenue method | $ 18,000 | |||||
Unearned revenue recognized under units-of-revenue method, current | 1,700 | 1,700 | 1,600 | |||
Unearned revenue recognized under units-of-revenue method, noncurrent | $ 10,800 | $ 10,800 | $ 11,700 | |||
HealthCare Royalty Partners II, L.P | First Royalty Sale Agreement | ||||||
Licensing and other arrangements | ||||||
Cash payment received | 6,500 | |||||
Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years | $ 4,000 | |||||
Number of milestone periods | period | 3 | |||||
HealthCare Royalty Partners II, L.P | Second Royalty Sale Agreement | ||||||
Licensing and other arrangements | ||||||
Cash payment received | $ 11,500 |
Royalty and Commercial Paymen_3
Royalty and Commercial Payment Purchase Agreements - Summary (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | |
Agreements | |||
Long-term royalty and commercial payment receivables | $ 66,575 | $ 66,575 | $ 69,075 |
Short-term royalty and commercial payment receivables | 2,500 | 2,500 | $ 0 |
Acquisition of royalty and commercial payment rights | $ 0 | 0 | |
Cash receipts for achievement of contractual milestones | $ 0 |
Royalty and Commercial Paymen_4
Royalty and Commercial Payment Purchase Agreements - Agenus (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Sep. 20, 2018 USD ($) item | Nov. 30, 2020 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | |
Agreements | |||||||
Payments related to purchase of royalty rights and other commercial payment rights | $ 13,500 | ||||||
Long-term royalty and commercial payment receivables | $ 66,575 | $ 66,575 | $ 69,075 | ||||
Cash receipts for achievement of contractual milestones | 0 | ||||||
Revenue from contracts with customers | $ 525 | $ 525 | 3,275 | $ 544 | |||
Impairment of long-term royalty receivable | 0 | 0 | |||||
Royalty Purchase Agreement | Merck Immuno-Oncology Product | Agenus | |||||||
Agreements | |||||||
Amount of milestone achieved | $ 10,000 | ||||||
Agenus | Royalty Purchase Agreement | |||||||
Agreements | |||||||
Payments related to purchase of royalty rights and other commercial payment rights | $ 15,000 | ||||||
Long-term royalty and commercial payment receivables | $ 15,000 | ||||||
Impairment of long-term royalty receivable | $ 0 | $ 0 | |||||
Agenus | Royalty Purchase Agreement | Incyte Immuno-Oncology Assets | |||||||
Agreements | |||||||
Royalties entity has right to receive (as a percent) | 33% | ||||||
Number of licensed products related to milestone and royalties | item | 6 | ||||||
Purchased percentage of milestones | 10% | ||||||
Agenus | Royalty Purchase Agreement | Merck Immuno-Oncology Product | |||||||
Agreements | |||||||
Royalties entity has right to receive (as a percent) | 33% | ||||||
Purchased percentage of milestones | 10% | ||||||
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones | $ 59,500 | ||||||
Amount of milestone achieved | 1,000 | ||||||
Cash receipts for achievement of contractual milestones | $ 1,000 |
Royalty and Commercial Paymen_5
Royalty and Commercial Payment Purchase Agreements - Bioasis (Details) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Nov. 02, 2020 USD ($) | Feb. 25, 2019 USD ($) agreement | Jun. 30, 2022 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | |
Agreements | ||||||
Payments related to purchase of royalty rights and other commercial payment rights | $ 13,500 | |||||
Long-term royalty and commercial payment receivables | $ 66,575 | $ 66,575 | $ 69,075 | |||
Contingent consideration under RPAs and CPPAs | 3,075 | 3,075 | 8,075 | |||
Impairment of long-term royalty receivable | 0 | 0 | ||||
Bioasis | Royalty Purchase Agreement | ||||||
Agreements | ||||||
Percentage of option to purchase royalty right on future license agreements | 1% | |||||
Number of future license agreements under optional purchase right | agreement | 2 | |||||
Obligation upon exercise of options per licensed product, second agreement | $ 300 | |||||
Obligation upon exercise of options per licensed product, third agreement | 400 | |||||
Payments related to purchase of royalty rights and other commercial payment rights | 300 | |||||
Long-term royalty and commercial payment receivables | 400 | |||||
Contingent consideration under RPAs and CPPAs | 100 | 100 | 100 | |||
Changes in estimated fair value of contingent consideration | 0 | |||||
Payments of contingent consideration | $ 0 | 0 | ||||
Impairment of long-term royalty receivable | 0 | 0 | ||||
Bioasis | Royalty Purchase Agreement | Maximum | ||||||
Agreements | ||||||
Potential future cash payments | $ 200 | |||||
Bioasis | Second Royalty Purchase Agreement | ||||||
Agreements | ||||||
Payments related to purchase of royalty rights and other commercial payment rights | $ 1,200 | |||||
Long-term royalty and commercial payment receivables | $ 1,200 | |||||
Impairment of long-term royalty receivable | $ 0 | $ 0 |
Royalty and Commercial Paymen_6
Royalty and Commercial Payment Purchase Agreements - Aronora (Details) $ in Thousands | 1 Months Ended | 6 Months Ended | 12 Months Ended | |
Apr. 07, 2019 USD ($) item | Sep. 30, 2019 USD ($) | Jun. 30, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Agreements | ||||
Long-term royalty and commercial payment receivables | $ 66,575 | $ 69,075 | ||
Contingent consideration under RPAs and CPPAs | 3,075 | 8,075 | ||
Impairment of long-term royalty receivable | 0 | 0 | ||
Aronora | Royalty Purchase Agreement | ||||
Agreements | ||||
Number of drug candidates | item | 5 | |||
Non-royalties to be received (as a percent) | 10% | |||
Future non-royalty payments to be received (as a percent) | 5% | |||
Multiplier for cumulative amount of consideration paid | item | 2 | |||
Upfront payment | $ 6,000 | |||
Threshold amount of cumulative royalties on net sales per product | 250,000 | |||
Aggregate milestones payments per product | 85,000 | |||
Long-term royalty and commercial payment receivables | 9,000 | |||
Contingent consideration under RPAs and CPPAs | 3,000 | |||
Payments of contingent consideration | $ 3,000 | |||
Impairment of long-term royalty receivable | $ 0 | $ 0 | ||
Aronora | Royalty Purchase Agreement | SVB Loan | ||||
Agreements | ||||
Upfront payment | $ 3,000 | |||
Aronora | Royalty Purchase Agreement | Bayer Products | ||||
Agreements | ||||
Number of drug candidates | item | 3 | |||
Number of drug candidates subject to exclusive license option | item | 1 | |||
Royalties entity has right to receive (as a percent) | 100% | |||
Non-royalties to be received (as a percent) | 10% | |||
Contingent future cash payment for each product | $ 1,000 | |||
Potential future cash payments | $ 3,000 | |||
Aronora | Royalty Purchase Agreement | Non-Bayer Products | ||||
Agreements | ||||
Number of drug candidates | item | 2 | |||
Non-royalties to be received (as a percent) | 10% |
Royalty and Commercial Paymen_7
Royalty and Commercial Payment Purchase Agreements - Palo (Details) $ in Thousands | 6 Months Ended | 12 Months Ended | ||
Sep. 26, 2019 USD ($) item | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | |
Agreements | ||||
Payments related to purchase of royalty rights and other commercial payment rights | $ 13,500 | |||
Long-term royalty and commercial payment receivables | $ 66,575 | $ 69,075 | ||
Impairment of long-term royalty receivable | 0 | 0 | ||
Palo | Royalty Purchase Agreement | ||||
Agreements | ||||
Number of drug candidates | item | 6 | |||
Payments related to purchase of royalty rights and other commercial payment rights | $ 10,000 | |||
Long-term royalty and commercial payment receivables | $ 10,000 | |||
Impairment of long-term royalty receivable | $ 0 | $ 0 |
Royalty and Commercial Paymen_8
Royalty and Commercial Payment Purchase Agreements - Viracta (Details) $ in Thousands | 6 Months Ended | 12 Months Ended | ||
Mar. 22, 2021 USD ($) item | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | |
Agreements | ||||
Payments related to purchase of royalty rights and other commercial payment rights | $ 13,500 | |||
Long-term royalty and commercial payment receivables | $ 66,575 | $ 69,075 | ||
Impairment of long-term royalty receivable | 0 | 0 | ||
Viracta | Royalty Purchase Agreement | ||||
Agreements | ||||
Number of drug candidates | item | 2 | |||
Payments related to purchase of royalty rights and other commercial payment rights | $ 13,500 | |||
Maximum amount of potential milestones and other payments receivable | 54,000 | |||
Amount of maximum consideration retained | 20,000 | |||
Maximum amount of potential regulatory and commercial milestones receivable | 57,000 | |||
Long-term royalty and commercial payment receivables | $ 13,500 | |||
Impairment of long-term royalty receivable | $ 0 | $ 0 |
Royalty and Commercial Paymen_9
Royalty and Commercial Payment Purchase Agreements - Kuros (Details) - USD ($) $ in Thousands | 1 Months Ended | 6 Months Ended | 12 Months Ended | |
Jul. 14, 2021 | May 31, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | |
Agreements | ||||
Long-term royalty and commercial payment receivables | $ 66,575 | $ 69,075 | ||
Short-term royalty and commercial payment receivables | 2,500 | 0 | ||
Impairment of long-term royalty receivable | $ 0 | 0 | ||
Kuros | Royalty Purchase Agreement | ||||
Agreements | ||||
Royalties entity has right to receive (as a percent) | 100% | |||
Pre-commercial milestone payments | $ 25,500 | |||
Upfront payment | 7,000 | |||
Potential future sales milestone payments | 142,500 | |||
Long-term royalty and commercial payment receivables | $ 7,000 | |||
Milestone payment received by Kuros | $ 5,000 | |||
Percentage of milestone payment received by Kuros that company is entitled to receive | 50% | |||
Short-term royalty and commercial payment receivables | $ 2,500 | |||
Impairment of long-term royalty receivable | $ 0 | $ 0 |
Royalty and Commercial Payme_10
Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended | ||
Jan. 28, 2022 | Oct. 06, 2021 | Jun. 30, 2022 | Dec. 31, 2021 | |
Agreements | ||||
Long-term royalty and commercial payment receivables | $ 66,575 | $ 69,075 | ||
Contingent consideration under RPAs and CPPAs | 3,075 | 8,075 | ||
Impairment of long-term royalty receivable | 0 | 0 | ||
Affitech | Commercial Payment Purchase Agreement | ||||
Agreements | ||||
Upfront payment | $ 6,000 | |||
Payments eligible to receive (as a percent) | 0.50% | 0.50% | ||
Commercial payment receivable term | 10 years | 10 years | ||
Maximum additional payments upon achievement of regulatory and sales milestones | $ 3,000 | $ 20,000 | ||
Long-term royalty and commercial payment receivables | 14,000 | |||
Maximum payable on regulatory milestone | 8,000 | |||
Maximum payable on sales milestone | 12,000 | |||
Milestone payment | 5,000 | |||
Maximum payable on regulatory milestone, Additional amount | 3,000 | |||
Maximum payable on sales milestone, Additional amount | $ 12,000 | |||
Impairment of long-term royalty receivable | 0 | 0 | ||
Affitech | Commercial Payment Purchase Agreement | Regulatory milestones | ||||
Agreements | ||||
Contingent consideration under RPAs and CPPAs | $ 8,000 | 3,000 | $ 8,000 | |
Affitech | Commercial Payment Purchase Agreement | Sales milestones | ||||
Agreements | ||||
Contingent consideration under RPAs and CPPAs | $ 0 |
Royalty and Commercial Payme_11
Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details) $ in Thousands | 6 Months Ended |
Jun. 30, 2022 USD ($) | |
Agreements | |
Short-term royalty receivable, Balance at beginning of period | $ 0 |
Reclassification to short-term royalty and commercial payment receivable | 2,500 |
Short-term royalty receivable, Balance at end of period | 2,500 |
Long-term royalty receivable, Balance at beginning of period | 69,075 |
Reclassification to short-term royalty and commercial payment receivable | (2,500) |
Long-term royalty receivable, Balance at end of period | $ 66,575 |
Fair Value Measurements - Finan
Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | |
Transfers between Levels | |||
Transfer into Level 3 | $ 0 | $ 0 | |
Transfer out of Level 3 | 0 | 0 | |
Level 1 to Level 2 transfers, Assets | 0 | 0 | |
Level 2 to Level 1 transfers, Assets | 0 | 0 | |
Level 1 to Level 2 transfers, Liabilities | 0 | 0 | |
Level 2 to Level 1 transfers, Liabilities | 0 | 0 | |
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount 1 | 0 | 0 | |
Fair Value, Assets, Level 2 to Level 1 Transfers, Amount 1 | 0 | 0 | |
Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount 1 | 0 | 0 | |
Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount 1 | 0 | 0 | |
Recurring | |||
Assets: | |||
Cash equivalents | 30,029 | 30,029 | |
Equity securities | 523 | 523 | $ 774 |
Total financial assets | 30,552 | 30,552 | |
Liabilities: | |||
Contingent consideration under RPAs and CPPAs | 3,075 | 3,075 | 8,075 |
Recurring | Money market funds | |||
Assets: | |||
Cash equivalents | 10,054 | 10,054 | |
Recurring | US treasury bills | |||
Assets: | |||
Cash equivalents | 19,975 | 19,975 | |
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | |||
Assets: | |||
Cash equivalents | 30,029 | 30,029 | |
Equity securities | 523 | 523 | 774 |
Total financial assets | 30,552 | 30,552 | |
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds | |||
Assets: | |||
Cash equivalents | 10,054 | 10,054 | |
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | US treasury bills | |||
Assets: | |||
Cash equivalents | 19,975 | 19,975 | |
Recurring | Significant Unobservable Inputs (Level 3) | |||
Liabilities: | |||
Contingent consideration under RPAs and CPPAs | $ 3,075 | $ 3,075 | $ 8,075 |
Fair Value Measurements - Estim
Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details) - $ / shares | Jun. 30, 2022 | Dec. 31, 2021 |
Closing Common Stock Price | ||
Fair Value Measurements | ||
Closing stock price (in dollars per share) | $ 3.23 | $ 4.78 |
Fair Value Measurements - Conti
Fair Value Measurements - Contingent Consideration (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | Oct. 06, 2021 | Feb. 25, 2019 | |
Fair Value Measurements | |||||
Contingent consideration under RPAs and CPPAs | $ 3,075 | $ 3,075 | $ 8,075 | ||
Bioasis | Royalty Purchase Agreement | |||||
Fair Value Measurements | |||||
Changes in estimated fair value of contingent consideration | 0 | ||||
Contingent consideration under RPAs and CPPAs | 100 | 100 | $ 100 | ||
Affitech | Commercial Payment Purchase Agreement | |||||
Fair Value Measurements | |||||
Changes in estimated fair value of contingent consideration | 0 | ||||
Affitech | Commercial Payment Purchase Agreement | Regulatory milestones | |||||
Fair Value Measurements | |||||
Contingent consideration under RPAs and CPPAs | 3,000 | 3,000 | $ 8,000 | $ 8,000 | |
Amount of milestone payment | 5,000 | ||||
Affitech | Commercial Payment Purchase Agreement | Sales milestones | |||||
Fair Value Measurements | |||||
Contingent consideration under RPAs and CPPAs | $ 0 | $ 0 |
Lease Agreement - Leased facili
Lease Agreement - Leased facilities (Details) - Leased facilities, Emeryville, California | 6 Months Ended |
Jun. 30, 2022 facility | |
Leases | |
Operating leases, number of leased facilities | 1 |
Option to extend lease | true |
Lease Agreement - Maturity of l
Lease Agreement - Maturity of lease liabilities (Details) $ in Thousands | Jun. 30, 2022 USD ($) |
Lease Agreement | |
2022 (excluding the six months ended June 30, 2022) | $ 101 |
2023 | 34 |
Total undiscounted lease payments | 135 |
Present value adjustment | (2) |
Total net lease liabilities | $ 133 |
Operating Lease, Liability, Statement of Financial Position | Operating lease liabilities, Long-term operating lease liabilities |
Lease Agreement - Lease costs (
Lease Agreement - Lease costs (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Lease costs | ||||
Operating lease cost | $ 44 | $ 44 | $ 88 | $ 88 |
Variable lease cost | 2 | 2 | 5 | 5 |
Total lease costs | $ 46 | $ 46 | $ 93 | $ 93 |
Lease Agreement - Additional in
Lease Agreement - Additional information (Details) - USD ($) $ in Thousands | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |
Lease Agreement | |||
Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases | $ 101 | $ 98 | |
Weighted-average remaining lease term, Operating leases | 8 months 1 day | 1 year 2 months 1 day | |
Weighted-average discount rate, Operating leases | 5.51% | 5.51% |
Common Stock Warrants (Details)
Common Stock Warrants (Details) - $ / shares | Jun. 30, 2022 | Dec. 31, 2021 |
Warrants | ||
Warrant outstanding (in shares) | 11,177 | 11,177 |
Ten Year Warrants Issued in May 2018 | ||
Warrants | ||
Exercise price of warrants (in dollars per share) | $ 23.69 | $ 23.69 |
Warrant outstanding (in shares) | 6,332 | 6,332 |
Common stock warrant, Exercise price $14.71 per share, Issued March 2019 | ||
Warrants | ||
Exercise price of warrants (in dollars per share) | $ 14.71 | $ 14.71 |
Warrant outstanding (in shares) | 4,845 | 4,845 |
Commitments and Contingencies -
Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details) $ in Millions | Jun. 30, 2022 USD ($) product |
Commitments and Contingencies | |
Estimate of milestone payments | $ | $ 6.3 |
Assumed number of products per contract | product | 1 |
Commitments and Contingencies_2
Commitments and Contingencies - Contingent Consideration (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||||
Sep. 30, 2019 | Jun. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | Oct. 06, 2021 | Apr. 07, 2019 | Feb. 25, 2019 | |
Commitments And Contingencies | |||||||
Contingent consideration under RPAs and CPPAs | $ 3,075 | $ 3,075 | $ 8,075 | ||||
Royalty Purchase Agreement | Bioasis | |||||||
Commitments And Contingencies | |||||||
Contingent consideration under RPAs and CPPAs | 100 | 100 | $ 100 | ||||
Payments of contingent consideration | 0 | 0 | |||||
Changes in estimated fair value of contingent consideration | 0 | ||||||
Royalty Purchase Agreement | Aronora | |||||||
Commitments And Contingencies | |||||||
Contingent consideration under RPAs and CPPAs | $ 3,000 | ||||||
Payments of contingent consideration | $ 3,000 | ||||||
Royalty Purchase Agreement | Aronora | Royalty milestones | |||||||
Commitments And Contingencies | |||||||
Contingent consideration under RPAs and CPPAs | 0 | 0 | |||||
Royalty Purchase Agreement | Kuros | Sales milestones | |||||||
Commitments And Contingencies | |||||||
Contingent consideration under RPAs and CPPAs | 0 | 0 | |||||
Commercial Payment Purchase Agreement | Affitech | |||||||
Commitments And Contingencies | |||||||
Changes in estimated fair value of contingent consideration | 0 | ||||||
Commercial Payment Purchase Agreement | Affitech | Regulatory milestones | |||||||
Commitments And Contingencies | |||||||
Contingent consideration under RPAs and CPPAs | 3,000 | 3,000 | $ 8,000 | $ 8,000 | |||
Commercial Payment Purchase Agreement | Affitech | Sales milestones | |||||||
Commitments And Contingencies | |||||||
Contingent consideration under RPAs and CPPAs | $ 0 | $ 0 |
Stock Based Compensation - ESPP
Stock Based Compensation - ESPP (Details) | 6 Months Ended |
Jun. 30, 2022 | |
2015 ESPP | |
Share-based compensation | |
Percentage of compensation of eligible employees to purchase shares of entity common stock at discount through payroll deductions | 85% |
Stock Based Compensation - Stoc
Stock Based Compensation - Stock Options (Details) - Stock Options | 6 Months Ended |
Jun. 30, 2022 | |
Share-based compensation | |
Minimum age required for employees to qualify for immediate vesting of award | 55 years |
Threshold years required for retirement age | 70 years |
Employees | |
Share-based compensation | |
Vesting period | 3 years |
Directors | |
Share-based compensation | |
Vesting period | 1 year |
Stock Based Compensation - Weig
Stock Based Compensation - Weighted Average Assumptions (Details) - Stock Options | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Weighted average assumptions | ||||
Dividend yield | 0% | 0% | 0% | 0% |
Expected volatility | 69% | 76% | 70% | 94% |
Risk-free interest rate | 2.90% | 1.06% | 2.17% | 0.77% |
Expected term | 5 years 7 months 9 days | 6 years | 5 years 7 months 24 days | 5 years 8 months 4 days |
Stock Based Compensation - St_2
Stock Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |
Share-based compensation | |||
Number of shares, Outstanding at beginning of period | 1,911,177 | ||
Number of shares, Granted | 222,972 | ||
Number of shares, Exercised | (101,811) | ||
Number of shares, Forfeited, expired or cancelled | (7,447) | ||
Number of shares, Outstanding at end of period | 2,024,891 | 1,911,177 | |
Number of shares, Exercisable at end of period | 1,571,458 | ||
Weighted Average Exercise Price Per Share, Outstanding at beginning of period | $ 20.64 | ||
Weighted Average Exercise Price Per Share, Granted | 19.83 | ||
Weighted Average Exercise Price Per Share, Exercised | 8.07 | ||
Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled | 31.04 | ||
Weighted Average Exercise Price Per Share, Outstanding at end of period | 21.15 | $ 20.64 | |
Weighted Average Exercise Price Per Share, Exercisable at end of period | $ 19.94 | ||
Weighted Average Contractual Term, Outstanding | 6 years 3 months 21 days | 6 years 3 months 29 days | |
Weighted Average Contractual Term, Exercisable | 5 years 5 months 19 days | ||
Aggregate Intrinsic Value, Outstanding | $ 16,048 | $ 15,103 | |
Aggregate Intrinsic Value, Exercisable | 15,414 | ||
Options exercised, aggregate intrinsic value | $ 2,100 | $ 1,500 | |
Weighted-average grant-date fair value (in dollars per share) | $ 12.21 | $ 27.89 | |
Stock Options | |||
Share-based compensation | |||
Unrecognized compensation expense related to stock options (in dollars) | $ 5,000 | ||
Weighted average period of unrecognized compensation expense expected to be recognized | 2 years 1 month 9 days |
Stock Based Compensation - St_3
Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Share-based compensation expense | ||||
Stock-based compensation expense | $ 837 | $ 768 | $ 1,815 | $ 3,666 |
General and administrative | ||||
Share-based compensation expense | ||||
Stock-based compensation expense | $ 837 | $ 768 | $ 1,815 | $ 3,666 |
Capital Stock - Dividends (Deta
Capital Stock - Dividends (Details) - $ / shares | Jul. 15, 2022 | May 18, 2022 | Apr. 15, 2022 | Mar. 17, 2022 | Jan. 18, 2022 | Oct. 20, 2021 |
8.625% Series A Cumulative, Perpetual Preferred Stock | ||||||
Dividends | ||||||
Cash dividend declared (in dollars per share) | $ 0.53906 | $ 0.53906 | $ 0.53906 | |||
Cash dividend paid (in dollars per share) | $ 0.53906 | $ 0.53906 | ||||
8.375% Series B Cumulative, Perpetual Preferred Stock | ||||||
Dividends | ||||||
Cash dividend declared (in dollars per share) | $ 0.52344 | $ 0.52344 | $ 0.52344 | |||
Cash dividend paid (in dollars per share) | $ 0.52344 | $ 0.52344 | ||||
Subsequent Event | 8.625% Series A Cumulative, Perpetual Preferred Stock | ||||||
Dividends | ||||||
Cash dividend paid (in dollars per share) | $ 0.53906 | |||||
Subsequent Event | 8.375% Series B Cumulative, Perpetual Preferred Stock | ||||||
Dividends | ||||||
Cash dividend paid (in dollars per share) | $ 0.52344 |
Capital Stock - BVF Ownership (
Capital Stock - BVF Ownership (Details) - BVF - Xoma Corporation - Common Stock | Jun. 30, 2022 |
Sale of stock | |
Ownership interest (as a percent) | 30.90% |
Ownership interest, if shares are converted (as a percent) | 51.90% |
Capital Stock - ATM Agreements
Capital Stock - ATM Agreements (Details) - USD ($) $ in Millions | 11 Months Ended | 42 Months Ended | |||
Aug. 05, 2021 | Mar. 10, 2021 | Dec. 18, 2018 | Jun. 30, 2022 | Jun. 30, 2022 | |
2018 Common Stock ATM Agreement | |||||
Sale of stock | |||||
Maximum amount of common shares to be issued | $ 30 | ||||
Shares issued (in shares) | 0 | ||||
Maximum amount of shares to be issued | $ 50 | ||||
2018 Common Stock ATM Agreement | Maximum | |||||
Sale of stock | |||||
Sales commission paid per transaction (as a percent) | 3% | ||||
2021 ATM Agreement | |||||
Sale of stock | |||||
Maximum amount of common shares to be issued | $ 50 | ||||
2021 ATM Agreement | Series B Depositary Shares | |||||
Sale of stock | |||||
Shares issued (in shares) | 0 | ||||
2021 ATM Agreement | Maximum | |||||
Sale of stock | |||||
Sales commission paid per transaction, preferred stock (as a percent) | 3% |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Income Taxes | ||||
Federal income tax provision | $ 0 | $ 0 | $ 0 | $ 0 |
Unrecognized tax benefits | 5.9 | 5.9 | ||
Unrecognized tax benefits that would impact effective tax rate | 0 | 0 | ||
Unrecognized tax benefits expected to change significantly over the next twelve months | 0 | 0 | ||
Accrued interest or penalties related to uncertain tax positions | $ 0 | $ 0 |